How Long Does Psilocybin's Antidepressant Effect Last?

Psilocybin & Depression

75% response at 12 months

In a 12-month follow-up at Johns Hopkins, 75% of patients who received two psilocybin sessions showed a clinically significant antidepressant response, and 58% were in full remission — GRID-HAMD scores dropped from 22.8 at baseline to 7.7 at 12 months (Cohen's d = 2.4).

Gukasyan et al., Journal of Psychopharmacology, 2022

Day 8

when antidepressant effects first became clinically measurable in the Davis 2021 Johns Hopkins RCT (JAMA Psychiatry, 2021)

92 days median

time to a depressive event for the COMPASS 25mg group vs 62 days for the 1mg comparator, across the 52-week follow-up (Goodwin et al., Journal of Clinical Psychiatry, 2025)

60–80%

cancer patients who retained significant antidepressant benefits at 3.2–4.5 year follow-up (Agin-Liebes et al., Journal of Psychopharmacology, 2020)

Gukasyan et al., Journal of Psychopharmacology, 2022

View as image ↗

Psilocybin clears the body within hours. The antidepressant effects that follow can last months to years. This disconnect between pharmacological duration and therapeutic duration is one of the most clinically significant features of psilocybin — and it is the central question every person considering this treatment asks first.

Based on clinical trial follow-up data, psilocybin's antidepressant effects typically become measurable within the first week, persist through 6 weeks in controlled trials, and remain meaningful in a substantial majority of patients at 12 months. In the longest follow-up studies to date, covering 3 to 5 years, a significant proportion of patients have retained benefits. The question "how long does psilocybin's antidepressant effect last" does not have a single answer, because the answer depends on the population studied, the dosing protocol, and what outcome you are measuring. But the data points in a consistent direction.

For an overview of what the full clinical trial record shows for efficacy, see Psilocybin for Major Depression: The Clinical Evidence. For the detailed month-by-month data table, see How Long Does Psilocybin's Antidepressant Effect Last? 3, 6, and 12 Month Data.

The Short Answer: Days to Years, Depending on What You Measure

Psilocybin's antidepressant effects, as measured in clinical trials across multiple populations and dosing protocols, follow a general pattern: onset within days, measurable improvement through controlled trial endpoints of 4–6 weeks, sustained high response rates through 12 months in open-label follow-up, and meaningful retention of benefit in multi-year observational studies.

Psilocybin is not a traditional daily antidepressant. Most trials involve one or two discrete treatment sessions, after which participants take no further psilocybin. The question of duration is therefore a question of how long a catalytic event sustains its effects — not how long a continuous treatment continues working.

The First Week: How Quickly Effects Appear

In the Davis 2021 Johns Hopkins randomized controlled trial (n=27), adults with moderate-to-severe major depressive disorder received two psilocybin sessions separated by two weeks.^[1] The trial tracked participants at multiple timepoints. By Day 8 — one week after the first session — participants showed a clinically significant reduction in depressive symptoms.

This rapid onset distinguishes psilocybin from conventional antidepressants, which typically require 4–6 weeks of daily dosing before clinical benefit appears. The neurological explanation is that psilocybin's acute effects on serotonin receptors trigger a cascade of neuroplasticity changes — including increased synaptic density and enhanced connectivity between previously siloed brain networks — that produce antidepressant effects within days rather than weeks.

By the 4-week endpoint, 71% of participants showed a clinically significant response and 54% were in full remission by the GRID-HAMD scale.^[1] These participants were then tracked forward in the Gukasyan 2022 follow-up study over the subsequent year.

At 12 Months: The Johns Hopkins Follow-Up

The Gukasyan 2022 study is the current benchmark for psilocybin's 12-month antidepressant durability.^[2]

The 24 participants from the Davis 2021 trial were followed for 12 months after their two psilocybin sessions. No additional treatment or psilocybin was administered during the follow-up period. The results: at 12 months, 75% of participants met criteria for a clinically significant response (substantial reduction in depression scores from baseline), and 58% met criteria for full remission.

The effect size at 12 months was a Cohen's d of 2.4 — meaning the average change in depression scores was 2.4 standard deviations from baseline. For context, conventional antidepressant drugs in placebo-controlled trials typically produce effect sizes of 0.3 to 0.5. The effect size in the Gukasyan follow-up is substantially larger than what standard antidepressants produce against active comparators, not against placebo.

The critical limitation of the Gukasyan data: there was no control group at the 12-month mark. The follow-up was observational. Some participants may have received other psychiatric treatment during the follow-up period. The 75% response rate reflects the real-world durability of the treatment in this open-label context, but it cannot be attributed to psilocybin alone in the way a controlled trial can.

At 6 Weeks and Beyond: The COMPASS Phase IIb Data

The COMPASS Pathways Phase IIb trial (n=233 treatment-resistant depression patients), published by Goodwin and colleagues in the New England Journal of Medicine, tested a single dose of synthetic psilocybin at three levels: 1mg, 10mg, and 25mg.^[3]

At the 3-week primary endpoint, the 25mg group showed significantly greater depression score reduction than the 1mg group — a 6.6-point larger drop on the MADRS depression scale.

A subsequent 52-week observational follow-up of this COMPASS cohort (the COMP 004 study) tracked how long that single dose held.^[4] Across all 233 original participants, the median time before a prespecified depressive event was 92 days in the 25mg group — compared to 83 days for the 10mg group and 62 days for the 1mg comparator — though the majority of patients in every dose group had experienced a depressive event by Week 12. The follow-up suggested that a single 25mg dose maintained its antidepressant effect longer than the lower doses, but the authors caution that larger long-term studies are still required to confirm this. This extension provides the most statistically powered single-dose duration data currently available, because it draws on the full 200-plus-participant trial rather than the 20–30 patients in most other follow-up studies.

The Quality-of-Life Advantage at 6 Months: What Escitalopram Comparisons Show

The Carhart-Harris et al. 2021 NEJM trial compared two doses of psilocybin therapy to six weeks of escitalopram (a standard SSRI) in 59 patients with moderate-to-severe MDD.^[9] At the primary 6-week endpoint, psilocybin was not significantly different from escitalopram on the primary depression measure, though it showed advantages on several secondary measures.

One Tie, Then Divergence

Psilocybin vs. Escitalopram Across Every Outcome the Trial Measured

Psilocybin (2× 25mg) Escitalopram (+ 1mg psilocybin)

Primary endpoint — QIDS-SR-16 change

Pre-specified primary measure, 6 weeks

Not significant (n=59)

-8.0 pts

-6.0 pts

Remission rate

Secondary outcome, QIDS-SR ≤ 5

Not significant (n=59)

57%

28%

Response rate

Secondary outcome, ≥50% score reduction

Not significant (n=59)

70%

48%

6-month psychosocial trajectory

Erritzoe 2024

Psilocybin

Advantage grew larger at 6 months than at 6 weeks

Escitalopram

Depression gains maintained; psychosocial gap widened

Emotional-face brain responsiveness (fMRI)

Wall 2025

Psilocybin

No reduction; slight increase to neutral faces

Escitalopram

Reduced BOLD response to emotional faces across regions

The primary endpoint difference was real but statistically non-significant because the 59-person Phase 2 trial was not powered to detect a 2-point scale gap — not because the treatments were equivalent.

Sources: Carhart-Harris et al., NEJM, 2021 (primary & secondary outcomes); Erritzoe et al., EClinicalMedicine, 2024 (6-month follow-up); Wall et al., Am J Psychiatry, 2025 (fMRI substudy).

Erritzoe, Carhart-Harris, and colleagues extended this comparison in a 2024 follow-up study.^[5] At 6 months after the end of the treatment period, psilocybin and escitalopram showed comparable reductions in depression symptom severity. But on the dimensions beyond depression scores — work functioning, social connectedness, and sense of meaning in life — psilocybin patients showed significantly greater sustained improvements than the escitalopram group.

This finding makes a distinction that standard depression scales do not capture. Measuring whether someone is "depressed" by symptom count may give the same result for both treatments, but measuring whether someone is functioning in their work, maintaining social relationships, and experiencing their life as meaningful gives a different picture at 6 months. Psilocybin patients showed greater gains on these secondary dimensions despite similar depression scores.

This quality-of-life advantage is consistent with what patients in long-term psilocybin follow-up studies consistently report: the drug reduces symptoms, but more distinctively, it shifts something about how they relate to their experience and their place in the world. The Agin-Liebes 2020 long-term cancer patient follow-up found that participants attributed sustained meaning and well-being improvements to their psilocybin experience years later — not just to symptom relief.^[6]

At 3-5 Years: What the Longest Follow-Up Data Shows

The longest available antidepressant follow-up data for psilocybin comes from a cancer-population study. Agin-Liebes and colleagues followed 16 patients who had received psilocybin-assisted therapy for depression and anxiety related to life-threatening cancer, and assessed them 3.2 to 4.5 years later.^[6]

At that multi-year follow-up, 60–80% of participants retained clinically significant antidepressant and anxiolytic benefits. The majority attributed sustained improvements in personal meaning, emotional openness, and attitude toward death directly to their psilocybin experience. Reductions in suicidal ideation and loss of meaning — two of the most clinically severe dimensions of depression — were also sustained at the long-term assessment.^[7]

For non-cancer MDD populations, a 2025 five-year follow-up study published in the Journal of Psychedelic Studies (DOI:10.1556/2054.2025.00461) found that approximately 67% of participants who responded to psilocybin-assisted therapy were still in remission at the 5-year mark — the longest published follow-up for this population. This study is not yet widely covered in clinical or consumer literature, but it represents the current outer boundary of duration evidence for non-cancer MDD.

A 2024 systematic review and meta-analysis confirmed that psilocybin produces significant and clinically meaningful depression reductions across multiple trials, with pooled effect sizes exceeding those of standard antidepressants.^[8]

Why Effects Last So Much Longer Than the Drug Stays Active

Psilocybin's active form (psilocin) is metabolized and cleared from the body in 4–6 hours. The antidepressant effects last months to years. This pharmacological paradox has an explanation rooted in neuroplasticity.

Psilocybin acutely activates the serotonin 5-HT2A receptor, which triggers a burst of synaptic plasticity — the growth of new dendritic spines and synaptic connections in prefrontal cortex and hippocampus. These structural changes persist after the drug has cleared. The result is a more flexible, better-connected brain architecture that maintains antidepressant function without ongoing drug stimulation.

Additionally, psilocybin's acute suppression of the default mode network — the brain circuit involved in self-referential rumination and rigid negative thought patterns — appears to reset habitual patterns of thinking during the session. If that reset results in new experiential patterns and insights (as psychotherapy integration aims to facilitate), those behavioral and cognitive changes can be self-sustaining.

The mechanistic picture is explored in depth in Psilocybin and the Default Mode Network: How It Quiets the Ego and How Psilocybin Treats Depression Differently Than SSRIs.

What These Studies Cannot Tell Us

The clinical picture on psilocybin's antidepressant duration is genuinely positive, but important limitations shape how to interpret it.

Most 12-month and multi-year follow-up data comes from open-label observational studies without active control groups. Spontaneous remission, regression to the mean, and other interventions received during the follow-up period cannot be ruled out as contributing factors. The Davis/Gukasyan Johns Hopkins cohort had 24 participants — a meaningful sample for a feasibility study but too small to draw definitive population-level conclusions.

The populations studied are not fully representative. Cancer patients with depression may have a different profile than the general MDD population. Treatment-resistant depression patients (COMPASS) respond differently than first-presentation MDD patients. Participant selection and preparation quality (who gets enrolled in academic trials with extensive support structures) are not the same as what might be achieved in a future clinical rollout.

No maintenance dosing protocol has been established. The question of what to do when effects begin to fade — if and when they do — is not well-answered by current evidence. For what the current evidence shows about multiple sessions, see Do You Need Multiple Psilocybin Sessions for Lasting Depression Relief?.

The overall evidence picture supports psilocybin as producing unusually durable antidepressant effects compared to standard treatments. It does not yet support claims of permanent cure, and does not give clear guidance on individual-level duration prediction.

Context

Moderate

Durability data comes from supervised trials, not self-treatment

Concern

The response and remission rates on this page were achieved with pharmaceutical-grade psilocybin, medical screening, and hours of trained psychological support before, during, and after dosing. Outside that clinical container — including with unregulated or mislabeled products, or in people with a personal or family history of psychosis or bipolar disorder — the safety and durability profile can be very different, and psilocybin remains a Schedule I substance under U.S. federal law.

What the research says

Every long-term figure here is from a research setting; none of it establishes that psilocybin is safe or effective as a self-directed treatment.

Particularly relevant for: Anyone considering psilocybin for depression outside an approved clinical trial or supervised program

What to do

This article is educational information, not medical advice. If you are living with depression, talk to a qualified clinician before making any treatment decision, and do not stop a prescribed antidepressant on your own.

Davis et al., 2021; Gukasyan et al., 2022; Goodwin et al., 2022, 2025

The Bottom Line

Psilocybin's antidepressant effects become measurable within one week, with trial-endpoint response rates of 71% at 4 weeks, 75% at 12 months, and 60–80% at multi-year follow-up in the available studies. A 2024 follow-up of the Imperial College escitalopram comparison found that psilocybin patients showed significantly greater improvements in work functioning, social connectedness, and sense of meaning at 6 months — dimensions SSRIs did not match. The durability extends far beyond the 4–6 hour pharmacological window, explained by psilocybin-induced neuroplasticity changes that persist after drug clearance. Key limitation: most long-term data comes from open-label observational follow-ups without control groups.

Frequently Asked Questions

Is psilocybin a permanent cure for depression?

No existing clinical data supports calling psilocybin a permanent cure. It produces unusually durable antidepressant effects — 75% response at 12 months in one follow-up study, 60–80% retention at 3–4 years in a cancer patient cohort — but these are observational results, not controlled trials. A proportion of patients relapse over time, and most trials note that some participants sought additional treatment during follow-up periods. The evidence supports characterizing psilocybin as capable of producing sustained remission for many patients, not permanent cure for all patients.

How long does psilocybin therapy last?

The acute pharmacological effects last 4–6 hours. Antidepressant effects in clinical trials become measurable by Day 8, show response rates of 71% at 4 weeks (Davis 2021), 75% at 12 months (Gukasyan 2022), and 60–80% retention at 3–4 year follow-up in cancer patients (Agin-Liebes 2020). In the 52-week follow-up of the COMPASS Phase IIb trial, median time before a depressive event was 92 days after a single 25mg dose (Goodwin 2025). Individual duration varies substantially based on dosing protocol, population, and individual factors.

Does psilocybin work after just one session?

Yes — single-dose protocols have demonstrated significant and durable antidepressant effects. The COMPASS trial used a single 25mg dose, and its 52-week follow-up found a median of 92 days before a depressive event. A 2023 JAMA trial of single-dose psilocybin for non-treatment-resistant MDD showed significant reductions through Day 43, the primary endpoint.^[10] Multiple sessions (as used in the Hopkins protocol) may offer advantages for some patients, but the evidence base does not require two sessions for clinically meaningful benefit.

How long do the effects of psilocybin on the brain last?

The neurological changes psilocybin induces include increased synaptic density (dendritic spine growth in prefrontal cortex, documented in rodent studies) and altered brain network connectivity patterns. These structural changes persist beyond the 4–6 hour acute pharmacological window. Functional neuroimaging studies in humans show altered default mode network and amygdala activity patterns weeks to months after a psilocybin session. These persistent brain changes are the proposed mechanism for why the antidepressant effects outlast the drug's active duration — the neuroplasticity continues to support improved mood regulation after psilocybin has cleared.

Sources & References

1. 1RTHM-00682·Davis, Alan K et al. (2021). “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial..” JAMA psychiatry.Study breakdown →PubMed →↩
2. 2RTHM-01529·Gukasyan, Natalie et al. (2022). “Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
3. 3RTHM-00761·Goodwin, Guy M et al. (2022). “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression..” The New England journal of medicine.Study breakdown →PubMed →↩
4. 4RTHM-00926·Goodwin, Guy M et al. (2025). “Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder..” The Journal of clinical psychiatry.Study breakdown →PubMed →↩
5. 5RTHM-01887·Erritzoe, David et al. (2024). “Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial..” EClinicalMedicine.Study breakdown →PubMed →↩
6. 6RTHM-01160·Agin-Liebes, Gabrielle I et al. (2020). “Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
7. 7RTHM-01425·Ross, Stephen et al. (2021). “Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer..” ACS pharmacology & translational science.Study breakdown →PubMed →↩
8. 8RTHM-01948·Metaxa, Athina-Marina et al. (2024). “Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis..” BMJ (Clinical research ed.).Study breakdown →PubMed →↩
9. 9RTHM-00675·Carhart-Harris, Robin et al. (2021). “Trial of Psilocybin versus Escitalopram for Depression..” The New England journal of medicine.Study breakdown →PubMed →↩
10. 10RTHM-00848·Raison, Charles L et al. (2023). “Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial..” JAMA.Study breakdown →PubMed →↩